Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 9Not yet recruiting 3Recruiting 2Completed 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 12Gastrointestinal 8Tumor-Agnostic 3Head & Neck 3Breast 3Gynecologic 2CNS 2Sarcoma 1Other solid neoplasm 1Endocrine 1

Conditions

Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Advanced Endometrial Cancer 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × anlotinib × Gynecologic × Clear all
NCT04574284 2025-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
170 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05130515 2023-01-31

CC-ANNIE

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Completed
6 enrolled
Gynecologic

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡